[go: up one dir, main page]

CO2017009008A2 - Oligómeros antisentido de tau - Google Patents

Oligómeros antisentido de tau

Info

Publication number
CO2017009008A2
CO2017009008A2 CONC2017/0009008A CO2017009008A CO2017009008A2 CO 2017009008 A2 CO2017009008 A2 CO 2017009008A2 CO 2017009008 A CO2017009008 A CO 2017009008A CO 2017009008 A2 CO2017009008 A2 CO 2017009008A2
Authority
CO
Colombia
Prior art keywords
antisense oligomers
tau
tau antisense
expression
tau protein
Prior art date
Application number
CONC2017/0009008A
Other languages
English (en)
Inventor
Richard E Olson
Angela M Cacace
Peter Hagedorn
Anja Mølhart Høg
Marianne Lerbech Jensen
Niels Fisker Nielsen
Dong Li
Jeffrey M Brown
Stephen E Mercer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2017009008A2 publication Critical patent/CO2017009008A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de oligómeros (oligómeros), que se dirigen a ARNm Tau en una célula, lo que conduce a una expresión menor de la proteína Tau. La reducción de la expresión de la proteína Tau es beneficiosa para el tratamiento de ciertos trastornos médicos, por ejemplo, un trastorno neurológico.
CONC2017/0009008A 2015-02-04 2017-09-01 Oligómeros antisentido de tau CO2017009008A2 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562112058P 2015-02-04 2015-02-04
US201562156684P 2015-05-04 2015-05-04
US201562237922P 2015-10-06 2015-10-06
US201562238941P 2015-10-08 2015-10-08
US201662279610P 2016-01-15 2016-01-15
US201662279614P 2016-01-15 2016-01-15
US201662279612P 2016-01-15 2016-01-15
PCT/US2016/016646 WO2016126995A1 (en) 2015-02-04 2016-02-04 Tau antisense oligomers and uses thereof

Publications (1)

Publication Number Publication Date
CO2017009008A2 true CO2017009008A2 (es) 2017-11-21

Family

ID=55443327

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0009008A CO2017009008A2 (es) 2015-02-04 2017-09-01 Oligómeros antisentido de tau

Country Status (24)

Country Link
US (3) US10799523B2 (es)
EP (2) EP3253875B1 (es)
JP (1) JP2018505676A (es)
KR (1) KR20180016970A (es)
CN (1) CN107922946A (es)
AU (1) AU2016215155A1 (es)
BR (1) BR112017016663A2 (es)
CA (1) CA2975525A1 (es)
CL (1) CL2017001956A1 (es)
CO (1) CO2017009008A2 (es)
CR (1) CR20170359A (es)
DK (1) DK3253875T3 (es)
HK (1) HK1248276A1 (es)
IL (1) IL253730A0 (es)
MA (1) MA41586A (es)
MX (1) MX2017010066A (es)
PE (1) PE20171766A1 (es)
PH (1) PH12017550069A1 (es)
RU (1) RU2017127609A (es)
SG (1) SG11201706293XA (es)
TW (1) TW201641691A (es)
UY (1) UY36550A (es)
WO (1) WO2016126995A1 (es)
ZA (1) ZA201705119B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
KR102674612B1 (ko) * 2016-12-01 2024-06-14 상가모 테라퓨틱스, 인코포레이티드 Tau 조절제 및 그것의 전달을 위한 방법 및 조성물
MX2020005680A (es) * 2017-12-01 2020-08-20 Texas A & M Univ Sys Tratamiento antisentido del sindrome de angelman.
SG11202006528XA (en) * 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
SG11202006526YA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
KR20200108315A (ko) 2018-02-09 2020-09-17 제넨테크, 인크. Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드
WO2019157531A1 (en) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
MA52149A (fr) * 2018-03-13 2021-01-20 Janssen Pharmaceutica Nv Oligonucléotides modifiés et méthodes d'utilisation dans les tauopathies
AU2019252812A1 (en) 2018-04-13 2020-10-01 Bristol-Myers Squibb Company Novel phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
WO2019233922A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
CN112567033A (zh) 2018-07-03 2021-03-26 豪夫迈·罗氏有限公司 用于调节Tau表达之寡核苷酸
SG11202103316TA (en) 2018-10-02 2021-04-29 Sangamo Therapeutics Inc Methods and compositions for modulation of tau proteins
KR20210149107A (ko) * 2019-04-03 2021-12-08 브리스톨-마이어스 스큅 컴퍼니 Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
EP3947677A1 (en) 2019-04-04 2022-02-09 F. Hoffmann-La Roche AG Oligonucleotides for modulating atxn2 expression
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
CN113950529A (zh) 2019-06-06 2022-01-18 豪夫迈·罗氏有限公司 靶向atxn3的反义寡核苷酸
MX2022003194A (es) * 2019-09-17 2022-04-11 Zynerba Pharmaceuticals Inc Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.
CA3166855A1 (en) 2020-01-16 2021-07-22 Bristol-Myers Squibb Company Reagents and their use for modular enantiodivergent synthesis of c-p bonds
US20230203486A1 (en) * 2020-03-30 2023-06-29 Alnylam Pharmaceuticals, Inc. MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4162047A1 (en) 2020-06-09 2023-04-12 Roche Innovation Center Copenhagen A/S Guanosine analogues for use in therapeutic polynucleotides
AR124227A1 (es) 2020-12-03 2023-03-01 Hoffmann La Roche Oligonucleótidos antisentido que actúan sobre atxn3
AR124229A1 (es) 2020-12-03 2023-03-01 Hoffmann La Roche Oligonucleótidos antisentido que actúan sobre atxn3
WO2022125984A1 (en) * 2020-12-11 2022-06-16 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
JP2024506709A (ja) * 2021-02-17 2024-02-14 キュー－ステート バイオサイエンシーズ， インコーポレイテッド Ｕｂｅ３ａアンチセンス治療剤
US20240279656A1 (en) * 2021-06-29 2024-08-22 Shape Therapeutics Inc. Engineered Guide RNAs and Polynucleotides
MX2024003519A (es) 2021-09-24 2024-04-01 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
US20250304958A1 (en) * 2022-05-13 2025-10-02 Julius-Maximilians-Universität Würzburg Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease
KR20250119484A (ko) * 2024-01-30 2025-08-07 소바젠 주식회사 Mtor 활성 또는 발현을 조절하기 위한 화합물 및 이의 용도

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5453491A (en) 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
AU1784992A (en) 1991-04-19 1992-11-17 Schering Corporation Subunit of the human interleukin-3 receptor
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
EP0922102B1 (en) 1996-07-03 2010-04-21 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
US6159462A (en) 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
GB9812127D0 (en) 1998-06-06 1998-08-05 Univ Glasgow Detection of neural activity
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
CA2360396A1 (en) 1998-12-30 2000-07-13 Andrew M. Scharenberg Characterization of a calcium channel family
PT1141015E (pt) 1999-01-06 2009-10-13 Genentech Inc Variantes mutantes do factor de crescimento do tipo insulina (igf)i
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
JP4308760B2 (ja) * 2002-07-12 2009-08-05 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング トランケートｔａｕタンパク質
DK1569661T3 (da) 2002-11-18 2010-01-11 Santaris Pharma As Antisense design
JP2006518197A (ja) 2003-02-10 2006-08-10 サンタリス・ファルマ・アクティーゼルスカブ ラス発現の改変のためのオリゴマー化合物
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US7919472B2 (en) 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
ATE513912T1 (de) 2006-05-05 2011-07-15 Isis Pharmaceuticals Inc Verbindungen und verfahren zur modulation der expression von sglt2
EP2066684B1 (en) 2006-05-11 2012-07-18 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
EP2410054B2 (en) 2006-10-18 2019-12-11 Ionis Pharmaceuticals, Inc. Antisense compounds
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
DK2176280T4 (en) 2007-07-05 2015-07-20 Isis Pharmaceuticals Inc 6-Disubstituerede bicykliske nukleinsyreanaloge
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
EP2285819B1 (en) 2008-04-04 2013-10-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
CN101812127B (zh) * 2009-02-19 2013-03-06 中国科学技术大学 微管结合蛋白及其编码基因与应用
US20100275274A1 (en) * 2009-04-28 2010-10-28 National Yang-Ming University Mouse model for depression, schizophrenia and alzheimer's disease
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2796809C (en) 2010-04-21 2019-05-28 Optosecurity Inc. Method and system for use in performing security screening
EP3067421B1 (en) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8778884B2 (en) 2011-05-26 2014-07-15 Fondazione Salvatore Maugeri Clinica del Lavora e Della Riabilitazione Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto
US9243291B1 (en) 2011-12-01 2016-01-26 Isis Pharmaceuticals, Inc. Methods of predicting toxicity
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
EP3336189A1 (en) 2012-04-20 2018-06-20 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20160138014A1 (en) 2012-10-12 2016-05-19 Isis Pharmaceuticals, Inc. Antisense compounds and uses thereof
JP6243919B2 (ja) * 2012-10-24 2017-12-06 フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー． ファオ．Ｆｒａｕｎｈｏｆｅｒ−Ｇｅｓｅｌｌｓｃｈａｆｔ Ｚｕｒ Ｆｏｒｄｅｒｕｎｇ Ｄｅｒ Ａｎｇｅｗａｎｄｔｅｎ Ｆｏｒｓｃｈｕｎｇ Ｅ． Ｖ． 微小管修飾化合物
US9014359B1 (en) 2013-01-11 2015-04-21 Time Warner Cable Enterprises Llc Generation of phone number lists and call filtering
KR20150130430A (ko) 2013-03-14 2015-11-23 아이시스 파마수티컬즈 인코포레이티드 타우 발현을 조절하는 조성물 및 방법
AU2014287063A1 (en) 2013-07-11 2016-01-28 The Trustees Of Columbia University In The City Of New York MicroRNAs that silence tau expression
TW202246503A (zh) * 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2016019063A1 (en) 2014-07-29 2016-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
JP6350987B2 (ja) 2014-08-04 2018-07-04 本田技研工業株式会社 ＧＨファミリー３に属する耐熱性β―キシロシダーゼ

Also Published As

Publication number Publication date
ZA201705119B (en) 2020-01-29
EP3253875B1 (en) 2020-01-08
US10799523B2 (en) 2020-10-13
AU2016215155A1 (en) 2017-08-17
US11077132B2 (en) 2021-08-03
IL253730A0 (en) 2017-09-28
RU2017127609A (ru) 2019-03-04
UY36550A (es) 2016-08-31
DK3253875T3 (da) 2020-04-14
SG11201706293XA (en) 2017-09-28
TW201641691A (zh) 2016-12-01
MA41586A (fr) 2017-12-13
EP3253875A1 (en) 2017-12-13
EP3653712B1 (en) 2022-11-30
JP2018505676A (ja) 2018-03-01
CN107922946A (zh) 2018-04-17
MX2017010066A (es) 2017-11-01
US20160237427A1 (en) 2016-08-18
KR20180016970A (ko) 2018-02-20
CR20170359A (es) 2017-11-24
WO2016126995A1 (en) 2016-08-11
HK1248276A1 (zh) 2018-10-12
PH12017550069A1 (en) 2018-02-05
US20180161356A1 (en) 2018-06-14
PE20171766A1 (es) 2017-12-21
CL2017001956A1 (es) 2018-06-01
BR112017016663A2 (pt) 2018-04-10
US20220143064A1 (en) 2022-05-12
CA2975525A1 (en) 2016-08-11
EP3653712A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
CO2017009008A2 (es) Oligómeros antisentido de tau
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
CO2018002598A2 (es) Compuestos para modular la expresión de angiotensinógeno, composiciones que los contienen y procesos para su producción
MX2016014140A (es) Composiciones y metodos para modular la expresion de pkk.
NZ755605A (en) Compositions for modulating tau expression
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
CO2018003828A2 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
MX2019002190A (es) Uso de pridopidina para tratar distonías.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX382225B (es) Composiciones y metodos para inhibir la expresion del gen de hidroxiacido-oxidasa 1 (glicolato-oxidasa) (hao1).
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
MX2016004319A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
CL2018002128A1 (es) Composiciones y métodos para el tratamiento de heridas crónicas
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.